Eligibility Requirements
What changed on this page. It once stated an income limit of 600% of the Federal Poverty Level, which is not how AbbVie publishes its criteria; AbbVie sets dollar limits by household size. On 13 October 2026 we could not retrieve AbbVie's income-criteria page to re-check that table, so this page no longer repeats any figure. Check the current table on abbvie.com.
One rule worth knowing if you have Medicare. Patients on Medicare Part D with low incomes may be asked to apply to the Medicare Extra Help / Low-Income Subsidy programme first. AbbVie publishes current criteria at abbvie.com and takes calls on 1-800-222-6885. Nothing on this page is medical advice or a guarantee of eligibility; the determination is made by AbbVie, not by us.
Cut the cost around your prescriptions
As an Amazon Associate I earn from qualifying purchases.
Covered Medications
The following medications are covered by Skyrizi Complete (via AbbVie):
How to Apply
- Speak with your healthcare provider about Skyrizi Complete (via AbbVie). Your doctor, nurse, or social worker can help determine if you qualify.
- Gather required documents: proof of income (tax return, pay stubs, or Social Security statement), valid prescription, and proof of U.S. residency.
- Submit your application online or by mail. Visit the program website below or call the program hotline for assistance.
- Wait for a decision. Approval times and delivery (to your home, your prescriber or a pharmacy) vary by programme, and the programme will tell you how your medicine will arrive.
Check If You Qualify
Use our free Assistance Finder tool to check eligibility for Skyrizi Complete (via AbbVie) and other programs that may help reduce your medication costs.
Open Assistance FinderTo see Skyrizi's copay card limit next to Cosentyx and Tremfya, read the three support programmes side by side; which brands publish a bridge while insurance decides shows that Skyrizi's page prints none.
Sources and standards behind this page
Drug coverage in the United States is governed by published rules rather than by any one insurer's summary, and the sources below are the primary ones. They are linked so a reader can check a claim without taking this page's word for it.
- FDA Orange Book publishes the therapeutic-equivalence ratings that decide whether a generic may be substituted for a brand-name drug.
- FDA generic drug facts sets out what "generic equivalent" means and what a manufacturer must prove.
- CMS prescription drug coverage defines the rules a Medicare drug plan formulary must follow and how it may change mid-year.
- Medicare.gov drug coverage (Part D) states what a Part D plan is required to offer a member.
- CMS prescription drug appeals documents the coverage-determination and exception process when a drug is denied.
- Medicare Plan Compare is the official tool for checking what a specific plan charges for a specific drug at a specific pharmacy.
- Drugs@FDA is the federal database of approved drug products, which establishes whether a covered product exists and in what form.
- DailyMed carries the current FDA labeling for every marketed drug product, including approved strengths and forms.
- MedlinePlus drug information is the National Library of Medicine's consumer reference for what a medication is and how it is used.
- FTC report on pharmacy benefit managers documents how the middlemen between an insurer and a pharmacy shape what a plan actually covers.
- National Library of Medicine maintains the drug and health databases the sources above draw on.
This page describes how coverage and formularies work. It is not medical advice, and a reader's own plan documents and prescriber decide what applies to them.
Frequently Asked Questions
Uninsured patients within AbbVie's published income limits can receive free Skyrizi through myAbbVie Assist. AbbVie publishes those limits by household size on abbvie.com; check the current table there. Apply through your dermatologist or gastroenterologist.
Yes, the Skyrizi Complete savings card can reduce copays to as low as $0 per dose for commercially insured patients, with a maximum annual benefit. The card covers all FDA-approved indications.
Yes, Skyrizi is FDA-approved for moderately to severely active Crohn's disease, and both the PAP and copay card cover this indication.
Related Resources
Get Prescription Savings Alerts
Leave your email for updates on patient assistance programs, drug price changes, and new savings opportunities. We have not started sending yet, and we will only email when we do.